A therapeutic vaccine targeting human papillomavirus type 16 (HPV16) induced regression in high-grade precancerous cervical lesions, according to the results from a phase II clinical trial.
The quadrivalent HPV vaccine, developed by multinational pharmaceutical company Merck, was approved on Jan 8 for males on the Chinese mainland. The vaccine targets HPV types 6, 11, 16 and 18. The ...